These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26250988)

  • 21. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
    Kleibl Z; Kristensen VN
    Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translational advances regarding hereditary breast cancer syndromes.
    Gage M; Wattendorf D; Henry LR
    J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rare, protein-truncating variants in
    Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF
    J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.
    Hsu HM; Wang HC; Chen ST; Hsu GC; Shen CY; Yu JC
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2024-32. PubMed ID: 17932350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort.
    McInerney NM; Miller N; Rowan A; Colleran G; Barclay E; Curran C; Kerin MJ; Tomlinson IP; Sawyer E
    Breast Cancer Res Treat; 2010 May; 121(1):203-10. PubMed ID: 19763819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer.
    He M; Di GH; Cao AY; Hu Z; Jin W; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2012 May; 133(1):111-6. PubMed ID: 21811815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.
    Zhang B; Beeghly-Fadiel A; Long J; Zheng W
    Lancet Oncol; 2011 May; 12(5):477-88. PubMed ID: 21514219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
    Southey MC; Goldgar DE; Winqvist R; Pylkäs K; Couch F; Tischkowitz M; Foulkes WD; Dennis J; Michailidou K; van Rensburg EJ; Heikkinen T; Nevanlinna H; Hopper JL; Dörk T; Claes KB; Reis-Filho J; Teo ZL; Radice P; Catucci I; Peterlongo P; Tsimiklis H; Odefrey FA; Dowty JG; Schmidt MK; Broeks A; Hogervorst FB; Verhoef S; Carpenter J; Clarke C; Scott RJ; Fasching PA; Haeberle L; Ekici AB; Beckmann MW; Peto J; Dos-Santos-Silva I; Fletcher O; Johnson N; Bolla MK; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Marme F; Burwinkel B; Yang R; Guénel P; Truong T; Menegaux F; Sanchez M; Bojesen S; Nielsen SF; Flyger H; Benitez J; Zamora MP; Perez JI; Menéndez P; Anton-Culver H; Neuhausen S; Ziogas A; Clarke CA; Brenner H; Arndt V; Stegmaier C; Brauch H; Brüning T; Ko YD; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova NV; Antonenkova NN; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Spurdle AB; Investigators K; ; Wauters E; Smeets D; Beuselinck B; Floris G; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Olson JE; Vachon C; Pankratz VS; McLean C; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Kristensen V; Alnæs GG; Zheng W; Hunter DJ; Lindstrom S; Hankinson SE; Kraft P; Andrulis I; Knight JA; Glendon G; Mulligan AM; Jukkola-Vuorinen A; Grip M; Kauppila S; Devilee P; Tollenaar RA; Seynaeve C; Hollestelle A; Garcia-Closas M; Figueroa J; Chanock SJ; Lissowska J; Czene K; Darabi H; Eriksson M; Eccles DM; Rafiq S; Tapper WJ; Gerty SM; Hooning MJ; Martens JW; Collée JM; Tilanus-Linthorst M; Hall P; Li J; Brand JS; Humphreys K; Cox A; Reed MW; Luccarini C; Baynes C; Dunning AM; Hamann U; Torres D; Ulmer HU; Rüdiger T; Jakubowska A; Lubinski J; Jaworska K; Durda K; Slager S; Toland AE; Ambrosone CB; Yannoukakos D; Swerdlow A; Ashworth A; Orr N; Jones M; González-Neira A; Pita G; Alonso MR; Álvarez N; Herrero D; Tessier DC; Vincent D; Bacot F; Simard J; Dumont M; Soucy P; Eeles R; Muir K; Wiklund F; Gronberg H; Schleutker J; Nordestgaard BG; Weischer M; Travis RC; Neal D; Donovan JL; Hamdy FC; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Schaid DJ; Kelley JL; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Butterbach K; Park J; Kaneva R; Batra J; Teixeira MR; Kote-Jarai Z; Olama AA; Benlloch S; Renner SP; Hartmann A; Hein A; Ruebner M; Lambrechts D; Van Nieuwenhuysen E; Vergote I; Lambretchs S; Doherty JA; Rossing MA; Nickels S; Eilber U; Wang-Gohrke S; Odunsi K; Sucheston-Campbell LE; Friel G; Lurie G; Killeen JL; Wilkens LR; Goodman MT; Runnebaum I; Hillemanns PA; Pelttari LM; Butzow R; Modugno F; Edwards RP; Ness RB; Moysich KB; du Bois A; Heitz F; Harter P; Kommoss S; Karlan BY; Walsh C; Lester J; Jensen A; Kjaer SK; Høgdall E; Peissel B; Bonanni B; Bernard L; Goode EL; Fridley BL; Vierkant RA; Cunningham JM; Larson MC; Fogarty ZC; Kalli KR; Liang D; Lu KH; Hildebrandt MA; Wu X; Levine DA; Dao F; Bisogna M; Berchuck A; Iversen ES; Marks JR; Akushevich L; Cramer DW; Schildkraut J; Terry KL; Poole EM; Stampfer M; Tworoger SS; Bandera EV; Orlow I; Olson SH; Bjorge L; Salvesen HB; van Altena AM; Aben KK; Kiemeney LA; Massuger LF; Pejovic T; Bean Y; Brooks-Wilson A; Kelemen LE; Cook LS; Le ND; Górski B; Gronwald J; Menkiszak J; Høgdall CK; Lundvall L; Nedergaard L; Engelholm SA; Dicks E; Tyrer J; Campbell I; McNeish I; Paul J; Siddiqui N; Glasspool R; Whittemore AS; Rothstein JH; McGuire V; Sieh W; Cai H; Shu XO; Teten RT; Sutphen R; McLaughlin JR; Narod SA; Phelan CM; Monteiro AN; Fenstermacher D; Lin HY; Permuth JB; Sellers TA; Chen YA; Tsai YY; Chen Z; Gentry-Maharaj A; Gayther SA; Ramus SJ; Menon U; Wu AH; Pearce CL; Van Den Berg D; Pike MC; Dansonka-Mieszkowska A; Plisiecka-Halasa J; Moes-Sosnowska J; Kupryjanczyk J; Pharoah PD; Song H; Winship I; Chenevix-Trench G; Giles GG; Tavtigian SV; Easton DF; Milne RL
    J Med Genet; 2016 Dec; 53(12):800-811. PubMed ID: 27595995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
    Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
    J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes.
    Singh K; Scalia J; Legare R; Quddus MR; Sung CJ
    Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
    Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
    Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
    Einarsdóttir K; Rosenberg LU; Humphreys K; Bonnard C; Palmgren J; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
    Breast Cancer Res; 2006; 8(6):R67. PubMed ID: 17132159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
    Easton DF; Lesueur F; Decker B; Michailidou K; Li J; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Dennis J; Ahmad J; Thompson ER; Damiola F; Pertesi M; Voegele C; Mebirouk N; Robinot N; Durand G; Forey N; Luben RN; Ahmed S; Aittomäki K; Anton-Culver H; Arndt V; ; Baynes C; Beckman MW; Benitez J; Van Den Berg D; Blot WJ; Bogdanova NV; Bojesen SE; Brenner H; Chang-Claude J; Chia KS; Choi JY; Conroy DM; Cox A; Cross SS; Czene K; Darabi H; Devilee P; Eriksson M; Fasching PA; Figueroa J; Flyger H; Fostira F; García-Closas M; Giles GG; Glendon G; González-Neira A; Guénel P; Haiman CA; Hall P; Hart SN; Hartman M; Hooning MJ; Hsiung CN; Ito H; Jakubowska A; James PA; John EM; Johnson N; Jones M; Kabisch M; Kang D; ; Kosma VM; Kristensen V; Lambrechts D; Li N; ; Lindblom A; Long J; Lophatananon A; Lubinski J; Mannermaa A; Manoukian S; Margolin S; Matsuo K; Meindl A; Mitchell G; Muir K; ; Nevelsteen I; van den Ouweland A; Peterlongo P; Phuah SY; Pylkäs K; Rowley SM; Sangrajrang S; Schmutzler RK; Shen CY; Shu XO; Southey MC; Surowy H; Swerdlow A; Teo SH; Tollenaar RA; Tomlinson I; Torres D; Truong T; Vachon C; Verhoef S; Wong-Brown M; Zheng W; Zheng Y; Nevanlinna H; Scott RJ; Andrulis IL; Wu AH; Hopper JL; Couch FJ; Winqvist R; Burwinkel B; Sawyer EJ; Schmidt MK; Rudolph A; Dörk T; Brauch H; Hamann U; Neuhausen SL; Milne RL; Fletcher O; Pharoah PD; Campbell IG; Dunning AM; Le Calvez-Kelm F; Goldgar DE; Tavtigian SV; Chenevix-Trench G
    J Med Genet; 2016 May; 53(5):298-309. PubMed ID: 26921362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
    Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
    Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
    Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
    Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.